デフォルト表紙
市場調査レポート
商品コード
1718940

日本の造影超音波市場の評価:製品別、用途別、エンドユーザー別、地域別、機会、予測、2019年~2033年度

Japan Contrast Enhanced Ultrasound Market Assessment, By Product, By Application, By End-user, By Region, Opportunities and Forecast, FY2019-FY2033F


出版日
ページ情報
英文 124 Pages
納期
3~5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
日本の造影超音波市場の評価:製品別、用途別、エンドユーザー別、地域別、機会、予測、2019年~2033年度
出版日: 2025年05月05日
発行: Market Xcel - Markets and Data
ページ情報: 英文 124 Pages
納期: 3~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

日本の造影超音波市場は、2026年から2033年度の予測期間中にCAGR6.61%を記録し、2025年の9,044万米ドルから2033年には1億5,086万米ドルに成長すると予測されています。日本では肝疾患と心血管疾患の有病率が高まっており、より安全で非侵襲的な診断ツールとして造影超音波(CEUS)の需要が高まっています。臨床医や患者の意識の高まりと超音波技術の進歩が相まって、病院や画像診断センターでの採用が加速しています。さらに、放射線を使用しない画像診断に対する政府の支援はCEUSの利点と一致しており、日常診断への統合をさらに後押ししています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 日本の造影超音波市場の展望(2019年~2033年)

  • 市場規模分析と予測
    • 金額別
    • 数量別
  • 市場シェア分析と予測
    • 製品別
      • 装置
      • 造影剤
      • ソフトウェアとサービス
    • 用途別
      • 診断用途
      • 治療用途
    • エンドユーザー別
      • 病院・外科センター
      • 診断画像センター
      • 外来手術センター
      • その他
    • 地域別
      • 北部(北海道・東北)
      • 中部(関東・中部)
      • 南部(関西、中国、四国、九州・沖縄)
    • 企業別市場シェア分析(上位5社とその他-金額別、2025年)
  • 2025年、市場マップ分析
    • 製品タイプ別
    • 用途別
    • エンドユーザー別
    • 地域別

第6章 バリューチェーン分析

第7章 需要供給分析

第8章 輸入と輸出の分析

第9章 ポーターのファイブフォース分析

第10章 PESTLE分析

第11章 価格分析

第12章 市場力学

  • 市場促進要因
  • 市場の課題

第13章 市場動向と発展

第14章 規制枠組みとイノベーション

第15章 競合情勢

  • 市場リーダー上位5社の競合マトリックス
  • 上位5企業のSWOT分析
  • 市場上位10の主要企業の情勢
    • Lantheus Medical Imaging, Inc.
      • 会社概要
      • 主要経営陣
      • 製品とサービス
      • 財務状況(報告通り)
      • 主要市場への注力と地理的プレゼンス
      • 最近の動向/コラボレーション/ パートナーシップ/合併と買収
    • GE HealthCare Technologies Inc.
    • Bracco Imaging SPA
    • Philips Holding USA Inc.
    • Siemens Medical Solutions USA, Inc.
    • Mindray Medical International Limited
    • Canon USA, Inc.
    • Esaote SPA
    • Samsung Electronics Co., Ltd
    • Guerbet SA

上記の企業は市場シェアに応じて注文を保留するものではなく、調査作業中に入手可能な情報に応じて変更される可能性があります。

第16章 戦略的提言

第17章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Japan Contrast Enhanced Ultrasound Market, By Value, In USD Million, FY2019-FY2033F
  • Figure 2. Japan Contrast Enhanced Ultrasound Market, By Volume, In Million Units, FY2019-FY2033F
  • Figure 3. Japan Contrast Enhanced Ultrasound Market Share (%), By Product, FY2019-FY2033F
  • Figure 4. Japan Contrast Enhanced Ultrasound Market Share (%), By Application, FY2019-FY2033F
  • Figure 5. Japan Contrast Enhanced Ultrasound Market Share (%), By End-user, FY2019-FY2033F
  • Figure 6. Japan Contrast Enhanced Ultrasound Market Share (%), By Region, FY2019-FY2033F
  • Figure 7. By Product Map-Market Size (USD Million) & Growth Rate (%), FY2025
  • Figure 8. By Application Map-Market Size (USD Million) & Growth Rate (%), FY2025
  • Figure 9. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2025
  • Figure 10. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025
目次
Product Code: MX13065

Japan contrast enhanced ultrasound market is projected to witness a CAGR of 6.61% during the forecast period FY2026-FY2033, growing from USD 90.44 million in FY2025 to USD 150.86 million in FY2033. Growing prevalence of liver and cardiovascular diseases in Japan is driving demand for Contrast Enhanced Ultrasound (CEUS) as a safer, non-invasive diagnostic tool. Rising awareness among clinicians and patients, combined with advancements in ultrasound technology, is boosting its adoption across hospitals and imaging centers. Additionally, government support for radiation-free imaging aligns with CEUS benefits, further encouraging its integration into routine diagnostics.

Rising Prevalence of Chronic Diseases and Geriatric Population

Japan is experiencing an increase in its aging population alongside a rising incidence of chronic illnesses, including liver, kidney, and cardiovascular diseases. Contrast-Enhanced Ultrasound (CEUS) has emerged as a favored diagnostic method in these fields due to its non-invasive nature, lack of ionizing radiation, and excellent safety profile, which is particularly advantageous for elderly and high-risk patients. It offers real-time vascular imaging, enabling healthcare providers to identify lesions and tumors with greater precision. The growing need for regular diagnostic assessments in chronic diseases further drives the adoption of CEUS. Moreover, Japan's healthcare system emphasizes early disease detection to minimize long-term care expenses, prompting hospitals to incorporate CEUS into their diagnostic offerings. For instance, according to Japan's Ministry of Internal Affairs and Communications, as of 2023, seniors (65+) made up 29.1% of the total population, highlighting the pressing need for chronic disease management solutions.

Technological Advancements and Integration with AI Fueling Growth

In Japan, Contrast-Enhanced Ultrasound (CEUS) is undergoing swift advancements, particularly through the incorporation of artificial intelligence (AI) and advanced imaging software. These innovations improve image quality, lessen reliance on operators, and facilitate real-time analysis, thereby increasing the efficiency and applicability of CEUS. Japanese companies are channeling investments into CEUS systems that feature AI-based lesion detection, automated quantification, and motion correction capabilities. The enhanced precision and diagnostic reliability provided by these systems are promoting their acceptance in hospitals and diagnostic facilities. Moreover, AI enhances the reproducibility of CEUS results-an important factor for widespread clinical implementation. These innovations align with Japan's broader focus on smart healthcare technologies to address labor shortages and improve patient outcomes. For example, Canon U.S.A., Inc., a leading global supplier of imaging solutions, has launched Aplio beyond, a versatile ultrasound system that combines clinical excellence, operational efficiency, and ergonomic design in a compact, quiet, and eco-friendly package. Tailored for ultrasound specialists working in hospitals, busy imaging centers, and advanced practices that manage substantial workloads and varied patient populations, it provides outstanding imaging capabilities for routine assessments, specialized investigations, and complex procedures.

Increasing Use of CEUS in Oncology and Liver Imaging

CEUS is gaining significant traction in oncology diagnostics, especially for liver cancer, which has high incidence rates in Japan. It offers superior lesion characterization, early tumor detection, and post-treatment follow-up capabilities, often outperforming CT or MRI in certain contexts. Given its ability to visualize micro-vascularization without nephrotoxic contrast agents, CEUS is now commonly used for patients with renal impairments-common among cancer patients. Hospitals are increasingly adopting CEUS for liver, breast, and prostate cancer screening, due to its repeatability and low risk. Moreover, CEUS-guided biopsies and ablations have improved precision and outcomes in cancer treatment. For example, in late 2023, researchers at Kyoto University published clinical outcomes showing that CEUS significantly improved the detection rate of hepatocellular carcinoma (HCC) in high-risk Japanese patients compared to conventional ultrasound.

Future Market Scenario (FY2026 - FY2033F)

The Japan Contrast Enhanced Ultrasound (CEUS) market is poised for strong growth due to increasing applications in liver disease diagnosis, oncology, and cardiovascular imaging. As Japan faces a high burden of chronic liver conditions and an aging population, demand for non-invasive, radiation-free diagnostic tools is surging. CEUS offers real-time, high-resolution imaging with minimal side effects, making it ideal for repeated use, especially among elderly and vulnerable patients. Technological advancements, rising healthcare expenditure, and a growing preference for point-of-care imaging are expected to further propel adoption. Additionally, collaborations between Japanese medical institutions and global imaging companies are accelerating CEUS-related clinical trials and technology integration, positioning the market for long-term growth in diagnostic and therapeutic applications

.

Key Players Landscape and Outlook

Key players in the contrast enhanced ultrasound industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, Canon U.S.A., Inc. partnered with Olympus to introduce their newest ultrasound device, the Aplio i800 EUS. This hybrid system is especially proficient in identifying small lesions in the pancreas, as stated by Akihiro Sano, the general manager of ultrasound systems at Canon during a press briefing in January 2024.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Japan Contrast Enhanced Ultrasound Market Outlook, FY2019-FY2033F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Equipment
      • 5.2.1.2. Contrast Agents
        • 5.2.1.2.1. Molecule-Targeted Microbubbles
        • 5.2.1.2.2. Nanoparticle Microbubbles
      • 5.2.1.3. Software and Services
    • 5.2.2. By Application
      • 5.2.2.1. Diagnostic Applications
        • 5.2.2.1.1. Nephrology
        • 5.2.2.1.2. Cardiology
        • 5.2.2.1.3. Others
      • 5.2.2.2. Therapeutic Applications
        • 5.2.2.2.1. Cardiology
        • 5.2.2.2.2. Oncology
        • 5.2.2.2.3. Vascular
        • 5.2.2.2.4. Others
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals And Surgical Centers
      • 5.2.3.2. Diagnostic Imaging Centers
      • 5.2.3.3. Ambulatory Surgery Center
      • 5.2.3.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. North [Hokkaido and Tohoku]
      • 5.2.4.2. Central [Kanto and Chubu]
      • 5.2.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
  • 5.3. Market Map Analysis, FY2025
    • 5.3.1. By Product Type
    • 5.3.2. By Application
    • 5.3.3. By End-user
    • 5.3.4. By Region

6. Value Chain Analysis

7. Demand Supply Analysis

8. Import and Export Analysis

9. Porter's Five Forces Analysis

10. PESTLE Analysis

11. Pricing Analysis

12. Market Dynamics

  • 12.1. Market Drivers
  • 12.2. Market Challenges

13. Market Trends and Developments

14. Regulatory Framework and Innovation

15. Competitive Landscape

  • 15.1. Competition Matrix of Top 5 Market Leaders
  • 15.2. SWOT Analysis for Top 5 Players
  • 15.3. Key Players Landscape for Top 10 Market Players
    • 15.3.1. Lantheus Medical Imaging, Inc.
      • 15.3.1.1. Company Details
      • 15.3.1.2. Key Management Personnel
      • 15.3.1.3. Products and Services
      • 15.3.1.4. Financials (As Reported)
      • 15.3.1.5. Key Market Focus and Geographical Presence
      • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 15.3.2. GE HealthCare Technologies Inc.
    • 15.3.3. Bracco Imaging S.P.A.
    • 15.3.4. Philips Holding USA Inc.
    • 15.3.5. Siemens Medical Solutions USA, Inc.
    • 15.3.6. Mindray Medical International Limited
    • 15.3.7. Canon U.S.A., Inc.
    • 15.3.8. Esaote S.P.A
    • 15.3.9. Samsung Electronics Co., Ltd
    • 15.3.10. Guerbet SA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer